Condition
Acute Lymphoblastic Leukemia, B-precursor
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Recruiting1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07003737Not ApplicableRecruitingPrimary
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
NCT02772198Phase 1UnknownPrimary
T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
Showing all 2 trials